Columbus, OH Clinical Trials Report — July 2026

Columbus residents who may qualify for a study should act now on trials expected to close within the next 90 days. There are 49 such recruiting studies in the city, including 2 that accept healthy volunteers. Columbus also opened 37 new trials in July, a substantial increase from 21 in May, bringing the city’s active recruiting total to 1,286 trials across 357 research facilities.

Closing windows include cancer, infection, and mental-health studies

Enrollment deadlines can move sooner than projected if a study reaches its participant target. The closing-soon list includes studies involving suicidal thoughts, acute myeloid leukemia, adenovirus infection, acute stress conditions, and breast cancer. The most frequently represented conditions are:

• Suicidal ideation (2 trials)
• Acute myeloid leukemia (1 trial)
• Adenovirus infection (1 trial)
• Acute stress disorder (1 trial)
• Acute stress reaction (1 trial)
• Acute myeloid leukemia in remission (1 trial)
• Allogeneic hematopoietic stem cell transplantation recipient (1 trial)
• Anatomic stage 0 breast cancer, AJCC v8 (1 trial)
• Anatomic stage I breast cancer, AJCC v8 (1 trial)

The closing-soon data identify 2 studies that accept healthy volunteers. People considering these opportunities should confirm whether they are still enrolling, since availability may depend on age, medical history, medication use, and screening requirements.

Ohio State and Nationwide Children’s lead local access

Columbus’s strongest research concentration is at Ohio State-affiliated cancer and academic facilities, along with Nationwide Children’s Hospital. Ohio State University Comprehensive Cancer Center has 235 recruiting trials, while Nationwide Children’s Hospital has 180. Several Ohio State listings appear under separate facility names, creating additional access points for oncology, pediatric, surgical, anesthesia, and other specialty research.

• Ohio State University Comprehensive Cancer Center (235 trials)
• Nationwide Children’s Hospital (180 trials)
• The Ohio State University (128 trials)
• Ohio State University (121 trials)
• The Ohio State University Wexner Medical Center (67 trials)
• Riverside Methodist Hospital (44 trials)
• Grant Medical Center (37 trials)
• Doctors Hospital (36 trials)
• Columbus Oncology and Hematology Associates Inc (31 trials)
• Research Site (30 trials)
• Mount Carmel East Hospital (28 trials)
• The Mark H Zangmeister Center (27 trials)

For people seeking cancer studies, Ohio State University Comprehensive Cancer Center and Columbus Oncology and Hematology Associates are prominent starting points. Nationwide Children’s Hospital is a major destination for pediatric research, while the Ohio State and Wexner Medical Center listings cover a broad range of conditions and procedures.

July’s new studies span behavioral, drug, and device research

Behavioral studies were the largest category among July’s openings, with 12 new trials. Drug studies followed with 10, and device studies accounted for 9. Other classifications included procedures, dietary supplements, diagnostic tests, and biological products. New condition categories included anxiety, several stages of breast cancer, chronic nausea, atopic dermatitis, back pain, anesthesia, and central nervous system tumors.

• NCT07684820 is a Phase 2 Expedition Therapeutics study of EXPD-101/FXS7553 versus placebo in people with COPD. The study plans to enroll 600 participants and uses once-daily treatment over 52 weeks.
• NCT07734415 is a Phase 2 Inmagene LLC study evaluating the long-term safety and effectiveness of IMG-007 in 400 participants with moderate-to-severe atopic dermatitis.
• NCT07702435, sponsored by Ohio State University Comprehensive Cancer Center, studies how different oral nicotine pouch messages communicate risk to young adults. It plans to include 607 participants.
• NCT07696338 is the REACT study of early airway-clearance therapies for people with cystic fibrosis, comparing approaches involving hypertonic saline and dornase alfa. The planned enrollment is 405 participants.
• NCT07699991, sponsored by Ohio State University Comprehensive Cancer Center, tests whether a navigation program improves survivorship-support participation among non-metastatic breast cancer survivors. It plans to enroll 330 participants.
• NCT07685730 is an Ohio State observational study comparing upper- and lower-extremity blood-pressure measurements during cesarean delivery under spinal or combined spinal-epidural anesthesia. It plans to include 327 participants.

The locally visible late-stage pipeline is currently led by Phase 2 studies rather than a reported Phase 3 opening. The Expedition Therapeutics COPD trial and Inmagene’s atopic dermatitis study offer opportunities for patients looking for sponsor-led drug research at Columbus sites, subject to local availability and eligibility.

Healthy volunteers and other eligibility groups

Of the 37 new July trials, 6 accept healthy volunteers. Across Columbus, 97 recruiting studies currently include healthy participants. These studies may involve behavioral research, diagnostic testing, devices, or other interventions rather than treatment for a disease.

July’s new studies include 6 trials that include children and 7 female-only studies. No new trial is listed as male-only, while 31 include older adults. Eligibility varies by protocol, so participants should review age ranges, health requirements, travel needs, visit schedules, and compensation details directly with each study team.

Academic research dominates the month. Ohio State University sponsors 19 new trials, and Ohio State University Comprehensive Cancer Center sponsors 5. Other listed sponsors include BrainChild Bio, BTL Industries, Dren Bio, Expedition Therapeutics, and Inmagene. The dataset classifies 32 new studies as other and 5 as industry-sponsored.

Other Ohio cities expand the search area

Participants willing to travel can also search in other Ohio research markets. Cleveland has 19 recruiting trials, Cincinnati has 11, and Dayton has 3. Fairborn, Mason, Mayfield Heights, Akron, and Sandusky each have 1 recruiting trial listed.

July’s opening total is the highest in the six-month trend shown: Columbus recorded 26 new trials in February, 22 in March, 18 in April, 31 in May, and 21 in June. With both new studies and near-term closing dates active at major Columbus facilities, patients and healthy volunteers should review eligibility and contact sites promptly as the second half of 2026 unfolds.